Optimizing the dose in patients treated with imatinib as first line treatment for gastrointestinal stromal tumours: A cost-effectiveness study.

Sander ZuidemaIngrid M E DesarNielka P van ErpWietske Kievit

Published in: British journal of clinical pharmacology (2019)

Based on the currently available data, this analysis suggests that TDM-guided dosing may be a cost-effective intervention for patients with metastatic/unresectable GIST treated with imatinib which will be improved when imatinib losses its patency.

Keyphrases

chronic myeloid leukemia
randomized controlled trial
electronic health record
big data
locally advanced
newly diagnosed
rectal cancer
deep learning